The Collaborative Cardiovascular Risk Reduction in Primary Care (CCARP) study

Pharmacotherapy
Charity D EvansDavid F Blackburn

Abstract

To evaluate whether a simple pharmacist protocol, consisting of patient screening and cardiovascular risk stratification, identification and reminders about uncontrolled risk factors, and drug adherence support, can significantly reduce cardiovascular risk. Prospective, randomized, controlled pilot study. Large primary care medical clinic in Saskatoon, Saskatchewan, Canada. One hundred seventy-six adult patients (mean age 60 yrs) who exhibited a 10-year Framingham risk score of 15% or greater, or a coronary artery disease risk equivalent (coronary artery disease, peripheral artery disease, cerebrovascular disease, or diabetes mellitus). Eligible patients initially met with the pharmacist to receive general counselling about cardiovascular disease and were then randomly assigned to receive ongoing follow-up by the pharmacist (follow-up group [88 patients]) or to return to usual care (single-contact group [88 patients]) for a minimum of 6 months. The primary end point was mean reduction in the 10-year Framingham risk score. Secondary end points included individual modifiable risk factors (systolic and diastolic blood pressures; total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol [HDL], and...Continue Reading

References

Jul 23, 2002·JAMA : the Journal of the American Medical Association·Joshua S BennerJerry Avorn
Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Jan 31, 2003·The Journal of Clinical Hypertension·Barry L CarterWilliam J Elliott
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Jun 7, 2006·The Canadian Journal of Cardiology·N A KhanUNKNOWN Canadian Hypertension Education Program
Apr 11, 2008·The Journal of Clinical Hypertension·Barry L CarterArthur J Hartz

❮ Previous
Next ❯

Citations

Apr 13, 2013·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Georgia PallikaronaYannis Tountas
Oct 29, 2013·Research in Social & Administrative Pharmacy : RSAP·Edwin C K TanJohnson George
Jul 24, 2014·International Journal of Clinical Pharmacy·Lucas Miyake OkumuraCassyano Januário Correr
May 31, 2014·Pharmacotherapy·Debbie A McCueAmy M Pick
Jun 17, 2015·Journal of the American Society of Hypertension : JASH·Tyler H GumsBarry L Carter
Oct 5, 2013·Canadian Pharmacists Journal : CPJ = Revue Des Pharmaciens Du Canada : RPC·Erin M YakiwchukDavid F Blackburn
May 3, 2014·The Cochrane Database of Systematic Reviews·Kate E LagerAndrew D Wilson
Nov 21, 2014·The Cochrane Database of Systematic Reviews·Robby NieuwlaatR Brian Haynes
Aug 24, 2018·Journal of Atherosclerosis and Thrombosis·Makoto KinoshitaUNKNOWN Committee for Epidemiology and Clinical Management of Atherosclerosis
Oct 23, 2017·BMJ Quality & Safety·Susan WellsDon Goldmann
Mar 16, 2017·The Cochrane Database of Systematic Reviews·Kunal N KarmaliMark D Huffman
May 10, 2020·The Cochrane Database of Systematic Reviews·Amanda J CrossJohnson George
May 8, 2018·The Cochrane Database of Systematic Reviews·Bernadeta BridgwoodPriya Modi
Mar 18, 2021·The International Journal of Pharmacy Practice·Matthew J Miller, Robert T Pammett
Aug 7, 2021·Research in Social & Administrative Pharmacy : RSAP·Natalie M WeirMarion Bennie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.